Active	Status	Sponsor type	Region	Phase	Filter
8 Active 0 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Welzel, Julia
ETSKABI, NCT04814511: Escalated Therapy of Scabies With INFECTOSCAB 5% (Permethrin)	Recruiting	3	183	Europe	InfectoScab 5 % Creme, Permethrin 10 % Creme, Driponin 3 mg Tabletten	Infectopharm Arzneimittel GmbH, Winicker Norimed GmbH	Scabies	12/22	08/23
Pivotal, NCT02938299 / 2015-002549-72: Neoadjuvant L19IL2/L19TNF- Study	Active, not recruiting	3	214	Europe	L19IL2 + L19TNF, Surgery	Philogen S.p.A.	Malignant Melanoma	10/24	12/28
KEYNOTE-D18, NCT05155254 / 2021-004594-32: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)	Active, not recruiting	3	407	Europe, US, RoW	IO102-IO103, Pembrolizumab	IO Biotech, Syneos Health, Merck Sharp & Dohme LLC	Metastatic Melanoma, Unresectable Melanoma	07/25	09/27
NCT05368285 / 2021-006413-11: A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria	Active, not recruiting	2	208	Europe, US, RoW	barzolvolimab, CDX-0159, Matching Placebo	Celldex Therapeutics	Chronic Spontaneous Urticaria	09/23	03/25
CDX0159-07, NCT05405660 / 2021-006447-95: A Study of CDX-0159 in Patients With Chronic Inducible Urticaria	Active, not recruiting	2	196	Europe, US, RoW	barzolvolimab, CDX-0159, Matching Placebo	Celldex Therapeutics, Celldex Therapeutics, Inc.	Chronic Inducible Urticaria	06/24	09/25
DUNCAN, NCT04362722 / 2020-003299-42: Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients	Recruiting	2	40	Europe	L19IL2 +L19TNF, bifikafusp alfa + onfekafusp alfa	Philogen S.p.A., Philogen S.p.A.	Carcinoma, Basal Cell, Carcinoma, Cutaneous Squamous Cell	09/24	09/24
NCT04971161 / 2020-004960-24: Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)	Active, not recruiting	2	152	Europe	allo-APZ2-CVU, Skin-derived ABCB5-positive dermal mesenchymal stromal cells, Placebo	RHEACELL GmbH & Co. KG, FGK Clinical Research GmbH	Skin Ulcer Venous Stasis Chronic	06/26	06/26
TRIM, NCT05750511: Multicenter Tissue Registry in Melanoma	Recruiting	N/A	1000	Europe	molecular tissue analysis	Dermatologic Cooperative Oncology Group	Metastatic Melanoma	02/24	02/25